vs
COLLEGIUM PHARMACEUTICAL, INC（COLL）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
COLLEGIUM PHARMACEUTICAL, INC的季度营收约是Rocket Lab Corp的1.1倍（$205.4M vs $179.7M），COLLEGIUM PHARMACEUTICAL, INC净利率更高（8.3% vs -29.5%，领先37.7%），Rocket Lab Corp同比增速更快（35.7% vs 12.9%），COLLEGIUM PHARMACEUTICAL, INC自由现金流更多（$122.4M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 19.1%）
Collegium制药是一家专科制药企业，专注于研发和商业化具备滥用威慑特性的创新疼痛管理疗法，主要面向美国市场，推出适用于慢性疼痛患者的缓释镇痛产品，服务覆盖基层及专科医疗领域的医护人员。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
COLL vs RKLB — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $205.4M | $179.7M |
| 净利润 | $17.0M | $-52.9M |
| 毛利率 | 62.5% | 38.0% |
| 营业利润率 | 29.6% | -28.4% |
| 净利率 | 8.3% | -29.5% |
| 营收同比 | 12.9% | 35.7% |
| 净利润同比 | 35.3% | -1.1% |
| 每股收益（稀释后） | $0.48 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $205.4M | $179.7M | ||
| Q3 25 | $209.4M | $155.1M | ||
| Q2 25 | $188.0M | $144.5M | ||
| Q1 25 | $177.8M | $122.6M | ||
| Q4 24 | $181.9M | $132.4M | ||
| Q3 24 | $159.3M | $104.8M | ||
| Q2 24 | $145.3M | $106.3M | ||
| Q1 24 | $144.9M | $92.8M |
| Q4 25 | $17.0M | $-52.9M | ||
| Q3 25 | $31.5M | $-18.3M | ||
| Q2 25 | $12.0M | $-66.4M | ||
| Q1 25 | $2.4M | $-60.6M | ||
| Q4 24 | $12.5M | $-52.3M | ||
| Q3 24 | $9.3M | $-51.9M | ||
| Q2 24 | $19.6M | $-41.6M | ||
| Q1 24 | $27.7M | $-44.3M |
| Q4 25 | 62.5% | 38.0% | ||
| Q3 25 | 61.7% | 37.0% | ||
| Q2 25 | 57.7% | 32.1% | ||
| Q1 25 | 54.8% | 28.8% | ||
| Q4 24 | 54.0% | 27.8% | ||
| Q3 24 | 60.8% | 26.7% | ||
| Q2 24 | 62.5% | 25.6% | ||
| Q1 24 | 63.1% | 26.1% |
| Q4 25 | 29.6% | -28.4% | ||
| Q3 25 | 29.7% | -38.0% | ||
| Q2 25 | 18.7% | -41.3% | ||
| Q1 25 | 12.2% | -48.3% | ||
| Q4 24 | 20.9% | -38.9% | ||
| Q3 24 | 21.9% | -49.5% | ||
| Q2 24 | 32.7% | -40.7% | ||
| Q1 24 | 34.1% | -46.4% |
| Q4 25 | 8.3% | -29.5% | ||
| Q3 25 | 15.0% | -11.8% | ||
| Q2 25 | 6.4% | -46.0% | ||
| Q1 25 | 1.4% | -49.5% | ||
| Q4 24 | 6.9% | -39.5% | ||
| Q3 24 | 5.9% | -49.6% | ||
| Q2 24 | 13.5% | -39.2% | ||
| Q1 24 | 19.1% | -47.7% |
| Q4 25 | $0.48 | $-0.09 | ||
| Q3 25 | $0.84 | $-0.03 | ||
| Q2 25 | $0.34 | $-0.13 | ||
| Q1 25 | $0.07 | $-0.12 | ||
| Q4 24 | $0.36 | $-0.11 | ||
| Q3 24 | $0.27 | $-0.10 | ||
| Q2 24 | $0.52 | $-0.08 | ||
| Q1 24 | $0.71 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $386.7M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $301.7M | $1.7B |
| 总资产 | $1.7B | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
| Q4 25 | $386.7M | $1.0B | ||
| Q3 25 | $285.9M | $976.7M | ||
| Q2 25 | $222.2M | $688.1M | ||
| Q1 25 | $197.8M | $428.4M | ||
| Q4 24 | $162.8M | $419.0M | ||
| Q3 24 | $120.0M | $442.4M | ||
| Q2 24 | $271.6M | $496.8M | ||
| Q1 24 | $318.0M | $492.5M |
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
| Q4 25 | $301.7M | $1.7B | ||
| Q3 25 | $274.8M | $1.3B | ||
| Q2 25 | $232.2M | $688.5M | ||
| Q1 25 | $234.4M | $431.3M | ||
| Q4 24 | $228.8M | $382.5M | ||
| Q3 24 | $234.3M | $419.8M | ||
| Q2 24 | $216.6M | $455.2M | ||
| Q1 24 | $222.2M | $478.9M |
| Q4 25 | $1.7B | $2.3B | ||
| Q3 25 | $1.6B | $2.2B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.7B | $1.2B | ||
| Q3 24 | $1.6B | $1.2B | ||
| Q2 24 | $1.1B | $1.2B | ||
| Q1 24 | $1.1B | $1.2B |
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $123.0M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $122.4M | $-114.2M |
| 自由现金流率自由现金流/营收 | 59.6% | -63.6% |
| 资本支出强度资本支出/营收 | 0.3% | 27.6% |
| 现金转化率经营现金流/净利润 | 7.25× | — |
| 过去12个月自由现金流最近4个季度 | $327.6M | $-321.8M |
8季度趋势，按日历期对齐
| Q4 25 | $123.0M | $-64.5M | ||
| Q3 25 | $78.4M | $-23.5M | ||
| Q2 25 | $72.4M | $-23.2M | ||
| Q1 25 | $55.4M | $-54.2M | ||
| Q4 24 | $84.6M | $-2.4M | ||
| Q3 24 | $-9.0M | $-30.9M | ||
| Q2 24 | $67.4M | $-13.0M | ||
| Q1 24 | $61.9M | $-2.6M |
| Q4 25 | $122.4M | $-114.2M | ||
| Q3 25 | $78.3M | $-69.4M | ||
| Q2 25 | $72.4M | $-55.3M | ||
| Q1 25 | $54.6M | $-82.9M | ||
| Q4 24 | $84.1M | $-23.9M | ||
| Q3 24 | $-9.2M | $-41.9M | ||
| Q2 24 | $67.1M | $-28.3M | ||
| Q1 24 | $61.4M | $-21.8M |
| Q4 25 | 59.6% | -63.6% | ||
| Q3 25 | 37.4% | -44.8% | ||
| Q2 25 | 38.5% | -38.3% | ||
| Q1 25 | 30.7% | -67.6% | ||
| Q4 24 | 46.2% | -18.1% | ||
| Q3 24 | -5.8% | -40.0% | ||
| Q2 24 | 46.2% | -26.7% | ||
| Q1 24 | 42.3% | -23.5% |
| Q4 25 | 0.3% | 27.6% | ||
| Q3 25 | 0.1% | 29.6% | ||
| Q2 25 | 0.0% | 22.2% | ||
| Q1 25 | 0.4% | 23.4% | ||
| Q4 24 | 0.3% | 16.3% | ||
| Q3 24 | 0.2% | 10.5% | ||
| Q2 24 | 0.2% | 14.4% | ||
| Q1 24 | 0.4% | 20.7% |
| Q4 25 | 7.25× | — | ||
| Q3 25 | 2.49× | — | ||
| Q2 25 | 6.05× | — | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — | ||
| Q1 24 | 2.23× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
COLL
暂无分部数据
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
